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RBM5 as a Putative Tumor Suppressor Gene
for Lung Cancer
Leslie C. Sutherland, PhD,*†‡ Ke Wang, MD, PhD,§ and Andrew G. Robinson, MD
Abstract: RBM5 is one member of a group of structurally related genes
that includes RBM6 and RBM10. RBM10 maps to Xp11.23, and one
allele is inactivated as a result of X chromosome inactivation. Both
RBM5 and RBM6 map to 3p21.3, a tumor suppressor region that
experiences loss of heterozygosity in the majority of lung cancers.
Overexpression of RBM5, which encodes an RNA-binding protein
involved in the regulation of alternative splicing and retards ascites
associated tumor growth in immunocompromised mice, a phenomenon
that may be related to an associated ability to modulate apoptosis. As
part of our quest to gain a better understanding of how the proapoptotic
activity of RBM5 might contribute to tumor suppressor function, we
reviewed all the literature relating to RBM5 expression, with a focus on
lung cancer. On the basis of the existing data, we suggest that—to more
thoroughly assess the potential involvement of RBM5 as a lung cancer
regulatory protein—more research is required regarding (a) the expres-
sion of not only full-length RBM5 but all of the alternate variants
associated with the locus, in relation to histologic subtype and smoking
history, and (b) the mutation status of various genes within the trans-
forming growth factor- signaling pathway, which may function to
either directly or indirectly regulate RBM5 activity in RBM5-retaining
lung cancers.
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Tumor Suppression Relating to 3p21.3
The earliest premalignant chromosomal aberration in
human lung cancers is allele loss within the short arm of
chromosome 3 at 3p21.3.1 This loss of heterozygosity occurs
in practically all (95%) small cell lung cancer (SCLC)
tumors, the majority (70%) of non-SCLC (NSCLC) tumors,
and in the normal bronchial epithelium of some smokers and
former smokers.2–4 The smallest lung cancer-specific deletion
region (based on homozygous deletion studies relating to 3
established SCLC cell lines (GLC20, NCI-H740, and NCI-
H1450) spans 370 kb, 19 genes (RBM6, RBM5, SEMA3F,
GNAT1, NAT1/SLC38A3/G17, GNAI2, SEMA3B, IFRD2,
HYAL3, FUS2/NAT6, HYAL1, HYAL2, FUS1/TUSC2,
RASSF1/123F2, BLU/ZMYND10, NPRL2/TUSC4, 101F6/
TSP10/CYB561D2, PL6/TMEM115, and CACNA2D2), and
3 open reading frames encoding hypothetical proteins
(LOC100129060, LOC100287609, and C3orf45/FLJ38608).5
Most of the 19 genes demonstrate varying degrees of tumor
suppressor activity (related to the control of processes such as
cell differentiation, proliferation, signal transduction, and
apoptosis), and it has been suggested that all function to-
gether as a large, integrated, biologically functionally diverse
tumor suppressor unit.3
RBM5 (previously referred to as g15, LUCA-15, and
H37) is an RNA-binding protein that has the ability to
modulate apoptosis.6–13 As shown in Figure 1A, RBM5-
mediated apoptosis is associated with up-regulation of the
proapoptotic protein BAX, down-regulation of the antiapop-
totic proteins BCL-2 and BCL-XL, increased release of mi-
tochondrial cytochrome c into the cytosol and increased
activation of caspases 9 and 3.9,11–13 RBM5 modulates apo-
ptosis by regulating the alternative splicing of apoptosis-
associated premRNAs, such as CASP2 and FAS/CD95.14,15
Although previously dismissed as unlikely to be a tumor
suppressor gene, based on its lack of mutations and continued
expression in most lung cancers, it has since been established
that RBM5 is not alone in this characteristic, because muta-
tions seem to be rare in the 19 genes mapping to the common
deletion region.1,3,16 The fact that RBM5 was recently shown
to retard tumor growth when overexpressed, albeit from a
strong viral promoter, in either A9 mouse fibrosarcoma cells
or A549 lung adenocarcinoma cells injected intraperitoneally
into immunocompromised mice, suggests that it possesses at
least some tumor suppressor activity.13,17,18 In addition, mul-
tiple protein isoforms of RBM5 exist, each possessing apo-
ptosis modulatory activity, a function not inconsistent with
tumor suppressor activity.19 (Notably, many of the other 19
genes mapping to the common deletion region, including
FUS1,20 RASSF1A,21 SEMA3B,22 SEMA3F,16 HYAL1,16 and
CACNA2D2,23 have the ability to modulate apoptosis.) Fi-
nally, RBM5 is 1 of 9 down-regulated genes in the 17-gene
*Tumour Biology Group, Regional Cancer Program of the Sudbury Regional
Hospital; †Faculty of Medicine, Biomolecular Sciences Program, and
Departments of Biology and Chemistry/Biochemistry, Laurentian Uni-
versity, Sudbury, Canada; ‡Faculty of Medicine, University of Ottawa,
Ottawa, Ontario, Canada; §Department of Respiratory Medicine, The
Second Affiliated Hospital of Jilin University, Changchun, Jilin, China;
and Medical Oncology, Regional Cancer Program, Sudbury Regional
Hospital, Sudbury, Ontario, Canada.
Disclosure: The authors declare no conflicts of interest.
Address for correspondence: Leslie C. Sutherland, PhD, Tumour Biology
Group, Department of Research, Regional Cancer Program of the Hoˆpital
Re´gional de Sudbury Regional Hospital, 41 Ramsey Lake Road, Sud-
bury, Ontario, Canada P3E 5J1. E-mail: lesutherland@hrsrh.on.ca
Copyright © 2010 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/10/0503-0294
Journal of Thoracic Oncology • Volume 5, Number 3, March 2010294
metastatic signature for solid tumors (including lung) in
humans and mice, suggesting that down-regulation of the
protein encoded by RBM5 is important for tumor establish-
ment and/or progression and in a wide range of cancers.24,25
Two smaller deletion regions at 3p21.3 have been
described after analyses of homozygous deletions common to
different cancer types. One deletion region, defined by
Senchenko et al.,26 was common to lung cancer cell lines,
renal cell carcinoma, and breast cancer biopsy samples; it
included the 17 genes listed earlier but excluded RBM5 and
RBM6. The second deletion region, defined by Minna et al.,27
was common to SCLC and breast cancer cell lines; it included
only 9 of the 19 genes defined by the 3 SCLC homozygous
deletions mentioned earlier and excluded RBM6, FUS2, and
all the genes between, including RBM5. Although these data
suggest that a subset of the deleted genes is associated with
SCLCs and might suffice for disease progression, the contri-
bution to malignant transformation of each of the 19 genes
within the larger deletion region that is common to the 3 lung
cancer cell lines, either individually or in tandem with other
genes, cannot be ruled out.
RBM5 Expression
Because loss of heterozygosity at 3p21.3 is more fre-
quent than loss of homozygosity, it means that expression of
genes mapping to this tumor suppressor region is theoreti-
cally detectable, unless expression of the remaining allele is
down-regulated by a process such as promoter hypermethyl-
ation. As expected, RBM5 expression is detectable in most
lung cancer cell lines and primary tissues (Table 1). The
question to be answered is how is the proapoptotic and
potential tumor suppressive activity of the remaining RBM5
allele silenced in lung cancers?
Inactivation of potential tumor suppressor activity can
be attributed to haploinsufficiency, but is more commonly a
result of gene mutation or transcriptional inactivation through
promoter hypermethylation (such as is the case for the 3p21.3
genes RASSF1A, BLU, SEMA3F, and SEMA3B in lung can-
cers).3,28 As is the case for the FUS1 tumor suppressor gene
that maps to 3p21.3, only a few RBM5 mutations have been
observed in lung cancer tumors, and RBM5 promoter hyper-
methylation does not seem to account for any observed
reduced or absent expression.1,28–30 This suggests that, like
FUS1, RBM5 expression and function in lung cancers are
regulated at another level.
Before we conclude that promoter hypermethylation is
not responsible for reduced RBM5 expression levels in lung
cancer, however, it should be noted that there is evidence that
promoter hypermethylation is related to both histologic sub-
type and smoking exposure.31 Promoter hypermethylation of
specific genes was noted with a higher frequency in lung
adenocarcinomas than squamous cell lung cancers.31 Within
the adenocarcinoma subtype, promoter hypermethylation was
more frequent in ever smokers than never smokers, and
within the ever smoker subgroup, promoter hypermethylation
was more frequent in current smokers than in former smok-
ers.31 In the RBM5 promoter hypermethylation study, neither
histologic subtype nor smoking history was considered.28
With reference to an earlier study by Oh et al.,17 however, it
FIGURE 1. The relationship be-
tween transforming growth factor
(TGF)- and RBM5 signaling and
the modulation of apoptosis. A,
Proapoptotic activity associated
with RBM5 overexpression is asso-
ciated with down-regulation
BCL-XL and up-regulation of BAX
expression, and antisense RBM5
overexpression is associated with
the up-regulation of BCL-2 expres-
sion. Overexpressed RBM5 in-
creases cytochrome c release from
the mitochondria and activation of
caspases 9 and 3. B, Activating mu-
tations in epidermal growth factor
receptor (EGFR), HER2, or KRAS
result in increased growth and de-
creased apoptosis. For instance,
RBM5 expression is down-regulated
by the RAS activating mutant RAS
(G12V), which would result in apo-
ptosis inhibition. Likewise, increased
EGFR and HER2 activit ies can lead to
phosphorylation—and subsequent
inhibition of—the proapoptotic activ-
ity associated with the BCL2-associ-
ated agonist of cell death, BAD.
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would appear that the samples used in the promoter hyper-
methylation study consisted of six squamous tumor samples,
four adenocarcinomas, and one large cell carcinoma. The six
tumor samples with the most significantly reduced RBM5
mRNA levels were of the squamous type (more often than
not, associated with 3p21.3 loss and smoking, and not
as frequently associated with promoter hypermethyl-
ation),1,31,32 whereas three of the nine with the less signif-
icantly reduced RBM5 mRNA levels were adenocarcino-
mas (associated with both smokers and never smokers, but
only 50% of the time associated with 3p21.3 loss,1 and
more frequently associated with promoter hypermethyl-
ation31). The one tumor sample with no change in RBM5
mRNA expression compared with its nontumor counter-
part was an adenocarcinoma, whereas the one tumor sam-
ple that had more RBM5 mRNA than its nontumor coun-
terpart was a large cell carcinoma. These results would
certainly suggest that RBM5 gene expression is related to
histologic subtype in NSCLC and may be related to smok-
ing history. The results also suggest that promoter hyper-
methylation cannot be ruled out as an RBM5 inhibitory
mechanism, because the absence of promoter hypermeth-
ylation recorded by Oh et al. may have been related to
3p21.3 homozygous deletions in at least three of the
squamous tumor samples (generally smoking associated)
and a nonsmoking-related tumorigenic mechanism in the
TABLE 1. RBM5 Gene Expression in Lung Cancer Cell Lines and Primary Tumor Tissue Samples
Histological
Subtype Characteristics
Cell Lines (mRNA) Primary Tissue
RBM5 () Reference RBM5 () Reference mRNA Reference Protein Reference
SCLC 3p21.3 () smokers NCI-H82 1 GLC20 1
NCI-H146 1 H740 1, 17
NCI-H249 1 H1450 1
NCI-H524 1
NCI-H1514 1
NCI-H1618 1
NCI-H2141 1
NCI-H2171 1
NCI-H2227 1
GLC1 29
GLC2 29
GLC3 29
GLC4 29
GLC7 29
GLC8 29
GLC16 29
GLC34 29
GLC35 29
GLC36 29
GLC42 29
GLC45 18, 29
Adenocarcinoma 3p21.3 ()/3p21.3 ()
smokers and never
smokers
NCI-H358 1, 13 4 of 52 17 32 of 392 17
NCI-H838 1
NCI-H1435 Sutherland,
unpublished
NCI-H1742 1
NCI-H1793 Sutherland,
unpublished
NCI-H2077 1
A549 13
GLCA2 29
Squamous 3p21.3 () smokers SK-MES-1 13 5 of 52 17 11 of 172 17
NCI-H520 13
Large cell NCI-H460 1, 13 1 of 11 17 3 of 62 17
NCI-H1155 1
NCI-H1299 1, 13
Mesothelioma NCI-H290 1
NCI-H2052 1
2, down-regulated; 1, up-regulated; SCLC, small cell lung cancer.
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adenocarcinomas. We would argue that smoking history
should be investigated before definitively ruling out pro-
moter hypermethylation as a mechanism of RBM5 expres-
sion level reduction in lung cancer.
Other than these 11 matched lung tissue samples, the
only reports concerning RBM5 mRNA expression levels in
lung cancer involve cell lines, most of which seem to express
RBM5 at levels equivalent to levels observed in nontumor
cells, a phenomenon that might be related to long-term
culture-associated alterations in gene expression.1,13,18,26,29 A
single study, also by Oh et al.,17 examined the levels of
RBM5 protein: in a range of NSCLC primary tumor samples,
the levels varied but were generally decreased compared with
nontumor samples. Sixty-five percent and 82% of the squa-
mous cell carcinoma and adenocarcinoma samples, respec-
tively, showed a strong reduction in protein expression.
Notably, all mutation and expression studies relating to
RBM5, including Northern blotting, RT-PCR, and immuno-
histochemistry (refer to Table 1 for references), focused on
one isoform. RBM5 premRNA is alternatively spliced to
produce at least three protein coding variants, some with
opposing apoptotic functions.6,7,10 In addition, at least one
antisense noncoding mRNA is transcribed within the RBM5
gene locus.33 Finally, differential expression of transcription-
induced chimeras of RBM6 and RBM5 has been observed in
tumor tissue compared with nontumor tissue and among
tumor types.34 Regulation of RBM5 gene expression is, there-
fore, a complex process that should also be examined in
relation to histologic subtype and smoking history to more
clearly define the purported tumor suppressor role of RBM5.
Smoking Status, TGF- Signaling, and RBM5
Recent studies suggest that although all NSCLCs seem to
involve alterations in the transforming growth factor (TGF)-
pathway (Figure 1B), the alterations are likely to be different
depending on smoking exposure history.35 For instance, epider-
mal growth factor receptor (EGFR) activating mutations are
more often associated with never smoker-related lung cancers,
whereas KRAS activating mutations are more often associated
with smoking-related NSCLC. Interestingly, RBM5 is down-
regulated by the constitutively activated RAS mutant protein,
RAS(G12V), in rat embryonic fibroblast cells.36 In light of
these observations, it would perhaps be prudent to examine
the relationship between activating EGFR mutations or acti-
vating KRAS mutations and RBM5 gene expression or func-
tion in lung cancer. In addition, one of a number of potential
EGFR binding partners, the proto-oncoprotein HER2/ErbB2,
seems to be overactive in a small percentage of both SCLC
and never smoker-related NSCLC.37,38 These activating mu-
tations in EGFR, KRAS, and HER2 are mutually exclusive
events.39,40 Interestingly, HER2 overexpression has been shown
to affect the alternative splicing of RBM5.41 In light of these
recent advances regarding lung cancer signaling, we would like
to suggest that future studies relating to RBM5 expression and
potential tumor suppressor activity take into consideration not
only the histologic subtype but also the smoking history and
mutation status of genes within the TGF- signaling pathway
to get a more accurate assessment of the role played by
RBM5 in lung cancer initiation and/or progression. In light of
recent trends toward tailoring therapies to tumor subtype
and/or genotype, this new direction for putative tumor sup-
pressor gene functional analysis seems warranted.
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